Navigation Links
Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings
Date:1/15/2014

FRANKLIN, Ohio, Jan. 15, 2014 /PRNewswire/ -- A novel wearable injector slightly larger than an Oreo cookie may soon make it easy and painless for patients to self-inject prescription drugs in the large doses required to treat a wide range of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders. 

An emerging biologic drugs market is expected to grow to $220B by 2018, according to analysts.   Many of these drugs will require a new type of injector that does not exist today for self-administration of high volumes and high viscosities.

Mike Hooven, Enable Injections LLC's founder and CEO, will present a new drug delivery technology that addresses these needs to pharmaceutical executives at two meetings this month:

  • PepTalk, a meeting for developers of protein and antibody therapeutics, January 13-17 in Palm Springs, CA
  • Drug Delivery Partnerships, for developers of new and repurposed drugs, January 27-29 in Boca Raton, FL

"Having an injector like this, especially one that decreases pain, opens the door to new pharmaceuticals that wouldn't be possible without this revolutionary device," says Gary Ansel, MD, Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus.  "We're talking potential for huge cost savings, reduced hospital stays, and increased patient compliance—all at the push of a button."

Currently available for investigational use only, Enable's bolus injector uses standard vials, can automatically mix powdered/liquid vials, and may deliver doses as large as 20cc.  Patients would wear the disposable device under their clothing and comfortably go about their business during the infusion.  

"Enable has a world-class design team that has developed a unique technology to address this exciting new opportunity.  We're looking forward to working with our pharmaceutical partners to introduce these products to market," says Hooven, a medical device veteran who previously founded AtriCure, the first device company to obtain FDA clearance for the surgical treatment of atrial fibrillation. 

About Enable Injections
Enable Injections, LLC develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue.   The system uses a standard vial container closure, and can automatically mix lyophilized solutions.  Founded February 2010 by medical device industry veterans, the company has R&D and manufacturing facilities in Franklin, Ohio.


'/>"/>
SOURCE Enable Injections, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kareo Launches New Solution Center to Enable Private Practice Success
2. Ekahau RTLS Enables Asset and Temperature Tracking in Five VISN-10 Veterans Health Administration Hospitals and Two Clinics
3. Experian Healthcare launches tool to enable providers to identify and help enroll eligible individuals for health insurance exchange (HIX) subsidized programs
4. New Workflow to Provide Scientists with Tools That Enable Single Cell Analysis for Oncology, Immunology and Stem Cell Research
5. NW Bio Receives Regulatory Decision That Will Enable Its Phase III Brain Cancer Trial To Proceed In Germany
6. New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research
7. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
8. Patent Protection for TAL Effector Technology Enables Licensing Path for Life Technologies Customers
9. Varian Enables HIPAA Compliance and Optimizes Customer Service with the Axeda Machine Cloud
10. Cloud Enables Advances in Medical Imaging Innovation
11. Leica Biosystems and Dell Enable Access to Pathology Images Between China and the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):